Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.
about
Prediction of cancer drugs by chemical-chemical interactionsA phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium.Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000-2013).Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomasAdvances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategiesNew insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patients.Salvage therapy with mitoxantrone, etoposide, bleomycin and dexamethasone for refractory or relapsed aggressive non-Hodgkin's lymphoma patients with a poor performance status or comorbidity.Gemcitabine, navelbine, and doxorubicin as treatment for patients with refractory or relapsed T-cell lymphomaManagement of fertility in patients treated for Hodgkin's lymphoma.Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphomaMaximum standardized uptake value on positron emission tomography/computed tomography predicts clinical outcome in patients with relapsed or refractory diffuse large B-cell lymphoma.Hematopoietic stem cell gene therapy with drug resistance genes: an update.Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the ComPhase I study of docetaxel plus ifosfamide in patients with advanced cancer.Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-HTreatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.Dose intense therapy for relapsed lymphoproliferative disorders: the more things change, the more they are the same.Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group.Peripheral blood stem cell mobilization tactics.Management of relapsed-refractory diffuse large B cell lymphoma.Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma.Current clinical indications for plerixaforEffect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma.Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma.A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation.Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma.Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin's disease (Croatian experience).High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation.
P2860
Q28539449-9F1BA9E0-FDC6-4E1B-9C4E-1327DECB76CAQ30538453-0C1247F2-7AD7-4868-B88C-CC2375F4C68DQ33365711-A95FE98F-C3DD-4B34-9345-1B4B48DA70D6Q33401481-231BE31E-95CE-4FCF-80F5-B709FC4EEFAFQ33405357-DFADB66D-FE30-4646-8429-3A08AE695B51Q33426690-9C0A8018-ECE3-46F7-AE8A-228CB17CB2EDQ33728214-36EDB584-2669-4EAE-A0A3-FEEEE6B4FBA8Q33886267-88791A83-A7CD-4380-92BE-9BC21C82F6D7Q34114055-1DCCBCF3-1436-448F-A185-CA1AD6634ACBQ34293322-5D862297-2188-40BB-B9B0-BD3DB15BE39CQ35249315-759A4CDC-68C0-47FF-B24C-BA8333B50C13Q35528686-2C1FF5DA-FF32-4775-B5BF-E66D69A72E83Q35754532-E36286A7-23B5-43A0-846B-E49F998536C1Q35800656-C17299E3-B59F-4900-A244-CD406B45CE57Q36204222-67D58926-F222-4E68-9395-C26960C73102Q36264723-0DD7430A-C3C6-4B8F-89C2-25F95A29C9A0Q36452273-7DD06F23-A843-46B5-B646-97836AC43825Q36646143-79321A0A-C207-4171-A4F3-3A5AEB970A21Q36700470-A15F11B4-5C41-4077-AF71-09A6437A9D68Q36836092-2D7729B8-327D-4F72-A014-1E674D4FCB50Q37136655-1F22DAC3-1D2F-456B-8E1A-71599F081B03Q37178611-B96B7FA6-5C02-4F54-BEE8-009A45F4459EQ37216194-79CABAC1-25B3-4FF8-86B4-9AC7AEEE479BQ37487759-6A6D8BD6-0F77-466F-9C0A-FEFFFFC59759Q37526899-5D1B1B37-93FA-43F9-AF50-92FF626F0548Q37649251-3647E609-E94F-417F-AB70-D990AE0BDA49Q37654010-508558C3-1456-4E4A-ABCF-1A38D9D38484Q37713596-537692F7-CA01-412B-BD4F-E9F6CF04FCC5Q38177784-589E6624-EC70-46E2-ACB8-379F69D7295DQ38302368-41E40943-FB36-4DE9-B2A6-2D6FCCB4D083Q38642477-2010FB67-0C39-4E6A-AC70-45E0592ECC86Q39049318-ABA19FC6-C6D4-468D-B97C-88F8535CCB2DQ41080351-DF58C194-35C0-48AE-8712-566C9A64C216Q43583142-F4E1B45B-00C3-4205-BBB5-32C1604DF805Q43830902-42CEEEE0-1144-426A-92C1-0066CB72EB0FQ44103047-954499B4-F1A7-473D-B8A5-014D1D11A789Q44123961-9460C441-DACB-481A-A38B-9F54419E986AQ44177895-B5A88435-30CE-4CA6-8111-349A358E96A2Q44780860-259D8782-C5AA-4645-9E8D-7F537090320BQ45001844-D6A8B2D4-5A30-4AFA-833B-411843360E94
P2860
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Ifosfamide, carboplatin, and e ...... s with non-Hodgkin's lymphoma.
@ast
Ifosfamide, carboplatin, and e ...... s with non-Hodgkin's lymphoma.
@en
Ifosfamide, carboplatin, and e ...... s with non-Hodgkin's lymphoma.
@nl
type
label
Ifosfamide, carboplatin, and e ...... s with non-Hodgkin's lymphoma.
@ast
Ifosfamide, carboplatin, and e ...... s with non-Hodgkin's lymphoma.
@en
Ifosfamide, carboplatin, and e ...... s with non-Hodgkin's lymphoma.
@nl
prefLabel
Ifosfamide, carboplatin, and e ...... s with non-Hodgkin's lymphoma.
@ast
Ifosfamide, carboplatin, and e ...... s with non-Hodgkin's lymphoma.
@en
Ifosfamide, carboplatin, and e ...... s with non-Hodgkin's lymphoma.
@nl
P2093
P1476
Ifosfamide, carboplatin, and e ...... s with non-Hodgkin's lymphoma.
@en
P2093
A D Zelenetz
C H Moskowitz
C S Portlock
D S Straus
P304
P356
10.1200/JCO.1999.17.12.3776
P407
P577
1999-12-01T00:00:00Z